Literature DB >> 11022196

Organ-specific and non-organ-specific autoantibodies in children and young adults with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED).

R Perniola1, A Falorni, M G Clemente, F Forini, E Accogli, G Lobreglio.   

Abstract

OBJECTIVE: The aim of the study was to assess the complex of autoantibodies which can be detected in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), a rare autosomal recessive disease in which the extent of autoimmunity is still unknown.
DESIGN: Antibodies (A) to parathyroid glands, adrenal cortex (AC-A), ovary and testis (steroid cell antibodies, SC-A), pancreatic islet cells (IC-A), gastric parietal cells, and non-organ-specific antigens were investigated in 11 APECED patients living in the Salento region of southern Italy. Further measurements included antibodies to cytochrome P450 (CYP) enzymes: cholesterol side-chain cleavage enzyme (CYP11A), 21-hydroxylase (CYP21) and 17alpha-hydroxylase (CYP17); and to glutamic acid decarboxylase 65-kDa isoform (GAD65), tyrosine phosphatase-like protein IA2, thyroglobulin (TG), thyroperoxidase (TPO), thyrotropin receptor, liver CYP enzymes and intrinsic factor.
METHODS: Antibodies to organs and subcellular fractions were detected by immunofluorescence. Radiobinding, immunoradiometric, and immunoblotting assays were used for the other measurements.
RESULTS: AC-A and SC-A were positive in all sera; among antibodies to adrenal CYP enzymes, only CYP21-A were present in all the patients with Addison's disease of short-medium duration (<15 years). Of three patients with Addison's disease of long duration (>15 years), two tested positive for antibodies to all three CYP enzymes, and the other for only CYP11A-A. In all sera CYP11A-A and/or CYP17-A were found. Two patients tested positive for both IC-A and GAD65-A, one for both IC-A and IA2-A, and one for GAD65-A; the fasting C-peptide assay showed no statistical difference between these four subjects and the others. All four hypothyroid patients were positive for TPO-A, while two of them were positive and two were negative for TG-A; two euthyroid subjects had positivity for TG-A. Liver-kidney microsomal antibodies reacting against the CYP2A6 were detected in two patients with autoimmune hepatitis. All but one sera contained anti-nuclear antibodies at a titre ranging between 1:20 and 1:80; however, only two patients had a connective tissue disease (Sjögren's syndrome).
CONCLUSIONS: Several autoantibodies may be detected in any APECED patient. Our data confirm that CYP21-A and TPO-A are major autoantibodies involved in APECED-associated Addison's disease and hypothyroidism respectively, while CYP11A-A and CYP17-A correlate with positivity for SC-A. Markers of islet cell autoimmunity are frequent, but prevalence and modalities of progression to overt beta-cell failure have to be clarified. Low-titre non-organ-specific autoantibodies are a feature of autoimmunity in APECED, but their role has yet to be fully explained.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11022196     DOI: 10.1530/eje.0.1430497

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  21 in total

Review 1.  Lessons from primary immunodeficiencies: Autoimmune regulator and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.

Authors:  Gregory M Constantine; Michail S Lionakis
Journal:  Immunol Rev       Date:  2019-01       Impact factor: 12.988

Review 2.  Etiology and treatment of hypogonadism in adolescents.

Authors:  Vidhya Viswanathan; Erica A Eugster
Journal:  Pediatr Clin North Am       Date:  2011-10       Impact factor: 3.278

Review 3.  Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy.

Authors:  Kai Kisand; Pärt Peterson
Journal:  J Clin Immunol       Date:  2015-07-05       Impact factor: 8.317

4.  Autoimmune polyendocrinopathy-candidiasis-ectodermal-dystrophy (APECED) in Sicily: confirmation that R203X is the peculiar AIRE gene mutation.

Authors:  C Giordano; R Modica; M L Allotta; V Guarnotta; S Cervato; S Masiero; R Giordano; S Garelli; C Betterle
Journal:  J Endocrinol Invest       Date:  2011-09-27       Impact factor: 4.256

Review 5.  Etiology and treatment of hypogonadism in adolescents.

Authors:  Vidhya Viswanathan; Erica A Eugster
Journal:  Endocrinol Metab Clin North Am       Date:  2009-12       Impact factor: 4.741

6.  Effector mechanisms of the autoimmune syndrome in the murine model of autoimmune polyglandular syndrome type 1.

Authors:  Jason J Devoss; Anthony K Shum; Kellsey P A Johannes; Wen Lu; Anna K Krawisz; Peter Wang; Ting Yang; Norbert P Leclair; Cecilia Austin; Erich C Strauss; Mark S Anderson
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

Review 7.  Understanding systemic lupus erythematosus physiopathology in the light of primary immunodeficiencies.

Authors:  Magda Carneiro-Sampaio; Bernadete Lourdes Liphaus; Adriana Almeida Jesus; Clovis Artur A Silva; João Bosco Oliveira; Maria Helena Kiss
Journal:  J Clin Immunol       Date:  2008-04-11       Impact factor: 8.317

8.  Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy: insights into genotype-phenotype correlation.

Authors:  Donatella Capalbo; Lucia De Martino; Giuliana Giardino; Raffaella Di Mase; Iolanda Di Donato; Giancarlo Parenti; Pietro Vajro; Claudio Pignata; Mariacarolina Salerno
Journal:  Int J Endocrinol       Date:  2012-10-22       Impact factor: 3.257

9.  Absence of some common organ-specific and non-organ-specific autoimmunity in autoimmune polyendocrinopathy candidiasis ectodermal dystrophy.

Authors:  Nicolas Kluger; Kai Krohn; Annamari Ranki
Journal:  Endocr Connect       Date:  2013-02-25       Impact factor: 3.335

10.  Autoantibodies to IL-17A may be correlated with the severity of mucocutaneous candidiasis in APECED patients.

Authors:  Adrien Katalin Sarkadi; Szilvia Taskó; Gabriella Csorba; Beáta Tóth; Melinda Erdős; László Maródi
Journal:  J Clin Immunol       Date:  2014-02-04       Impact factor: 8.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.